The Board of Directors of Immunicum has announced that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately.

The Board has appointed Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, as acting CEO. The Board will begin recruitment of a new CEO shortly.

“We thank Carlos for his efforts that have put Immunicum in a strong position, with competitive clinical results and a competent and experienced organization with the ability to develop the company further. Over the past three years as CEO, Carlos has significantly contributed to steering the company through a demanding phase in the development of the drug candidate ilixadencel. Now is the right time to let a new CEO take Immunicum through its next development phase,” said Michael Oredsson, Chairman of the Board of Immunicum.

Listed on Nasdaq Stockholm

Carlos de Sousa was appointed CEO of Immunicum in October 2016. During his tenure, the company has, among other things, completed the liver cancer study (HCC), listed on Nasdaq Stockholm, initiated the multi-indication study ILIAD and entered into an agreement with Merck KGaA and Pfizer to study ilixadencel in combination with avelumab as part of ILIAD as well as completed the GIST and MERECA studies with promising results.

As Alex Karlsson-Parra is appointed acting CEO, Immunicum’s Senior Director of Business Development Sijme Zeilemaker has expanded his responsibility to the role of Chief Operating Officer. Immunicum’s Board of Directors will shortly begin recruitment of a new CEO to realize ilixadencel’s potential and build Immunicum’s value.